课题基金 / 基金详情

RADIOLABELED MONOCLONAL PAN B CELL ANTIBODY IN THE TREATMENT OF B CELL LYMPHOMAS

RADIOLABELED MONOCLONAL PAN B CELL ANTIBODY IN THE TREATMENT OF B CELL LYMPHOMAS
放射性标记单克隆泛 B 细胞抗体治疗 B 细胞淋巴瘤
批准号：
6274599
负责人：
MARK S. KAMINSKI
金额：
$2.15万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6274599
关键词：
B cell lymphoma antitumor antibody clinical research clinical trials human subject human therapy evaluation iodine monoclonal antibody neoplasm /cancer immunotherapy neoplasm /cancer radionuclide therapy radionuclides radiotracer

项目摘要

项目成果

MARK S. KAMINSKI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The main purpose of this study is to determine the efficacy of radioimmunotherapy using a monoclonal anti-CD20 antibody labeled with 131-I in patients with B-cell lymphoma who have relapsed after chemotherapy or who have not been previously treated. Our hypothesis is that this treatment may be superior to chemotherapy and that this can be assessed using molecular markers of minimal residual disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RETREATMENT OF NON HODGKINS LYMPHOMA W/ IODINE 131 ANTI B1 ANTIBODY
I 131 ANTI B1 ANTIBODY IN NON HODGKINS LYMPHOMA VS UNLABELED ANTI B1
(131) IODINE-B1 RADIOIMMUNOTHERAPY OF ADVANCED NONHODGKIN'S LYMPHOMA
(131) IODINE-B1 RADIOIMMUNOTHERAPY OF ADVANCED NONHODGKIN'S LYMPHOMA
海外基金